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1. INTRODUCTION 
Figure 1.1. 
Poppy plant (Papaver somniferum) 
1.1. History of opium, morphine, and heroin 
The poppy plant, Papaver somniferum (Fig. 1.1), is an annual herb native to 
Southeastern Europe and Western Asia. Latex containing several important alkaloids is 
obtained from its immature seed capsules 1-3 weeks after flowering. Incisions are made 
in the walls of the green seedpods, and the milky exudation is collected and dried. This is 
called opium. Opioid analgesics are of inestimable value because they reduce or abolish 
certain pain without causing a loss of consciousness, relieving coughs, spasms, fevers and 
diarrhea. 
Morphine was first isolated from opium in 1805 by Wilhelm Sertürner by 
dissolving it in acid then neutralizing it with ammonia. He named it morphium, after 
Morpheus, the Greek god of dreams. The discovery of morphine was considered a 
milestone. The medical community declared that opium had been "tamed". Morphine's 
reliability, long-lasting effects, and safety were extolled. In fact, despite its severe side 
effects (respiratory depression; confusion; severe drowsiness; weakness, dizziness; 
slurred speech; small, pinpoint pupils; cold, clammy skin; seizures; loss of consciousness; 
nausea or vomiting; constipation; itching; mood swings; euphoria; urinary retention; 
myoclonus; hallucinations; sweating and dependence leading to addiction etc.), it is still 
the premier drug used for extreme pain in hospitals and for end-of-life care. In 1843 
Alexander Wood discovered a new technique of administering morphine, injection with a 
syringe. 
Morphinism became rampant in the USA after its extensive use by injured 
soldiers during the Civil War. In late 19th century America, opiates were cheap, legal and 
abundant. Moreover it was believed that morphine wasn't addictive. Early optimism 
about morphine's non-addictive nature proved sadly misplaced. So the search began for a 
powerful non-addictive alternative to opium and morphine. In 1874 C.R. Alder Wright 
had boiled morphine and acetic acid to produce diacetylmorphine, C21H23O5N. The drug 
went unstudied until 1897 when Dreser working for the Bayer Company of Germany, 
found that the hydrochloride of diacetylmorphine, discovered by acetylation of morphine, 
is a drug without the common morphine side effects. They named it heroin after the 
Gennan word for hero, heroisch. Heroin is the most fast-acting of all the opiates. When 
injected, it reaches the brain in 15-30 seconds; smoked heroin reaches the brain in 7 
seconds. Heroin was considered a highly effective medication for coughs, chest pains, 
and the discomfort of tuberculosis. The Bayer Company started the production of heroin 
in 1898 on a commercial scale. Heroin was touted to doctors as stronger than morphine 
and safer than codeine. It was thought to be non-addictive, and even thought to be a cure 
for morphine addiction or for relieving morphine withdrawal symptoms. It has turned out, 
however, that repeated administration of heroin results in the development of tolerance 
and the patients become heroin-addicts soon. In the early 1910s morphine addicts 
"discovered" the euphorising properties of heroin and this effect was enhanced by 
intravenous administration. Heroin became a narcotic drug and its abuse began to spread 
quickly [55], 
1.2. Opioid receptors 
1.2.1. Opioid receptors: discovery, heterogeneity 
Specific receptors for opiates in the CNS have been postulated for many years 
[10, 120]. First demonstration of opioid receptors within the CNS was done by three 
independent research groups in 1973 using a rapid filtration binding assay [134, 156, 
112]. These early studies defined a saturable binding site, which bound opioids with 
nanomolar affinity. The sites were the first in which the binding of agonists and 
antagonists could be distinguished by sodium ions [113], and divalent cations [108, 169]. 
Evidence for multiple receptors came from the demonstration of different profiles of 
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pharmacological activity in the chronic spinal dog with the prototype agonists morphine, 
ketazocine and SKF 10047 [91]. Three types of opioid receptors were proposed named 
after the drugs used in the studies: p, K, and a. The 5-rcceptor was proposed to explain the 
in vitro activity of the enkephalins, and on naloxone to reverse endogenous opioid 
peptide inhibition of the nerve-evoked contractions of the mouse vas deferens [82], The 
o-receptor is targeted by PCP and its analogues [96], and it is no longer regarded as an 
opioid receptor. 
To date, there are three well-defined or "classical" types of opioid receptors MOP 
(p), KOP (K), DOP (5). 
Table 1.2.1. NC-IUPHAR proposal for opioid receptor nomenclature 
Current proposal Previous proposal 
p, mu, or MOP OP3 
8, delta, or DOP OP, 
K, kappa or KOP OP2 
1.2.2. Opioid receptor distribution and function 
Opioid receptors are widely distributed throughout the brain and periphery. In the 
periphery they are found in the myenteric plexus of the gut, in certain smooth muscles: 
ileum, vas deferens, and in adrenal medulla, heart, retina, placenta [27], 
Table 1.2.2. Distribution of opioid receptors in the CNS 
Opioid receptor Distribution in CNS Reference 
ft Highest densi ty: thalamus, caudate putamen, 
neocortex, nucleus accumbens, amygdala, 
interpeduncular complex, inferior- and superior 
colliculi, superficial layers of the dorsal horn of the 
spinal cord. 
M o d e r a t e densi ty: periaqueductal gray and raphe 
nuclei. 
[16,50,86] 
8 Highes t densi ty: olfactory bulb, neocortex, caudate 
putamen, nucleus accumbens, and amygdala. 
[86] 
K cerebral cortex, nucleus accumbens, claustrum and 
hypothalamus. 
[86], 
Opioid receptor activation by ligands results in a multitude of effects. In general, 
p- or 8-receptors selective agonists are analgesic and rewarding, K-receptor selective 
agonists are dysphoric [165]. 8-Receptors have a role in: analgesia [150], motor 
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integration, gastro-intestinal motility, olfaction, respiration, cognitive function, and mood 
driven behavior. Medullary 5-receptors are important in cardiovascular regulation [4]. K-
Receptors have a role in: nociception, diuresis, feeding and neuroendocrine secretions 
[48], control of immune function [52], thermoregulation [46] and modulation of 
cardiorespiratory function [49]. K-receptor agonists can produce dysphoria in humans 
[116]. p-Receptor agonists are potent antinociceptive drugs [111]. p-Receptors have a 
role in: respiration, cardiovascular functions, intestinal transit [36], feeding, learning and 
memory, locomotor activity, thermoregulation [47], hormone secretion, and immune 
functions, all of which, except hormone secretion, are depressed by p-receptor 
stimulation. The respiratory depressant effects of p-receptor agonists result from a 
decrease in sensitivity of respiratory centers to hypercapnia [19]. 
1.2.3. Molecular biology of opioid receptors 
Two independent groups, Kieffer [65] and Evans [34], cloned the first (mouse 8) 
opioid receptor using similar methods. The cloned mouse 8-receptor consists of 372 
amino acids. Hydropathy analysis suggests the presence of 7 TM domains within the 
amino acid sequence. Multiple phosphorylation sites may exist in the cytoplasmic loops 
and C-terminal. The rat [38], human [70] and amphibian (Rana pipiens) [149] 8-receptor 
has also been cloned. Although only one 8-receptor gene has been cloned, on the basis of 
in vitro and in vivo pharmacological characteristics, a variety of 5-receptor subtypes have 
been proposed: 81-, 82-, 8CX-, and Sncx-receptor [164, 123, 57, 128], 
Chen [22] isolated the first p-receptor cDNA clone. The rat p-receptor consists of 
398 amino acids. Five potential N-linked glycosylation sites are present in the N-
terminal. To date, p-receptor genes have also been cloned from mouse [94], human [167], 
Rhesus (Macaca mulatto) and crab-eating monkey (Macaca fascicularis) (G.M. Miller, 
B.K. Madras, direct GenBank deposit), pig (Sus scrofa) [107], cow (Bos tauras) [105], 
guinea pig (Cavia porcellus) (S.A. Smith, J.T. Stupfel, N.A. Ilias, G.D. Olsen, direct 
GenBank deposit), white suckerfish (Catostomus commersoni) [29], zebrafish (Danio 
rerio) [8], and frog (Rana pipiens) [149]. Weakly homologous sequences are also present 
in the genomes of Caenorhabditis elegans and Drosophila melanogaster. A variety of 
alternative mRNA splice variants have also been cloned and/or suggested for the p-
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receptor gene [109, 110] and some of the resulting proteins differ in their trafficking 
properties, although their pharmacology does not appear to differ in ligand binding assays 
[72], Thus, it is unlikely that these splice variants explain the observation of 
pharmacologically distinct p-receptor subtypes. The pi/p2 subdivision was proposed 
based on that [3H]labeled -p., -5 and -K ligands displayed biphasic binding characteristics 
[172, 74], Each radioligand appeared to bind to the same very high affinity site (pi) as 
well as to the appropriate high affinity site (p, 8 or K) depending on the radioligand used. 
Naloxazone and naloxonazine were reported to abolish the binding of each radioligand to 
the pi-site. While both pi and p2 receptors are involved in producing analgesia, euphoria 
is produced mainly through p h and respiratory depression through p2 receptors. 
The serendipitous cloning of the mouse K-receptor occurred during efforts to 
obtain mouse somatostatin receptor subtypes [174], The mouse K-receptor consists of 380 
amino acids. The K-receptor has two N-linked glycosylation sites in the N-terminal. A 
number of K-receptors subtypes have been described; KJ sites bind to dynorphin 1-17 but 
not to DADLE (representing the cloned K-receptors profile), K2 sites bind MERF and 
DADLE, and the so-called K3 site is sensitive to naloxone benzoylhydrazone [1], 
p-, 8- and K-Receptor subtypes may result from different posttranslational 
modifications of the gene product (glycosylation, palmytoylation, phosphorylation, etc), 
or from receptor oligomerization [28, 59]. 
The activity of known genes can be modified in vivo using gene-targeting 
technology. Mice lacking opioid peptides or receptors have been generated by 
homologous recombination [67]. p-Receptor deficient mice have been generated by 
disrupting exon 1 [139], exon 2 [92] or exons 2 and 3 [81]. All morphine responses 
investigated so far are nullified in p-receptor KO mice: analgesia after acute s.c. 
administration in tail immersion- [92], tail-flick- [139] and hotplate tests [139]; analgesia 
after intrathecal or i.e.v. administration [133]; respiratory depression [93]; constipation 
[129]; acute morphine treatment induced modification of locomotor activity [157]; 
euphoria [92]; chronic morphine treatment induced physical dependence, withdrawal 
symptoms [92]; chronic morphine treatment induced immunosuppression [40], The 
generation of mice deficient in 8-receptors was reported by Zhu et al. [179], and Filliol et 
al. [35]. Homologous recombination led to exon 1- or exon 2 deleted mice. Simonin et al. 
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reported mice lacking K-receptors [136]. Targeting was directed to delete the first coding 
exon. Mice lacking all three opioid receptor genes have been obtained in a two-step 
strategy. Breeding of mice lacking MOR exon 2 [92] with mice lacking KOR exon 1 
[136] produced MOR/KOR double mutants, while breeding of the former with exon 1 
DOR-deficient mice [35] produced MOR/DOR double mutants. Triple mutants were 
obtained from MOR/KOR x MOR/DOR matings. These animals showed no 
[3H]DAMGO, [3H]CI-977 and [3H]DPDPE binding sites, as expected from the parental 
phenotypes [137], The analysis of responses of MOR-, DOR- and KOR-deficient mice to 
prototypal opiates has clarified the role of each opioid receptor in the main actions of 
opiate drugs. The p- receptors are essential for the activity of morphine and trigger the 
large set of well-known opiate activities that are clinically useful or relevant to opiate 
addiction. The K-receptors mediate both dysphoric and analgesic activities of classical K-
agonists. 5-Receptors produce analgesia, do not mediate opioid reward and dependence 
and may have other roles, such as improving mood states. Finally, p- and 5-receptors may 
interact functionally while K-receptors act independently. 
m o r p h i n e , ^ j ^ o r p h l n 
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Fig.l.2.3.1. Opioid pharmacology and 
the knock out models 
1.2.4 Structure of the opioid receptors 
Opioid receptors belong to the membrane-bound class A (Rhodopsin) family of 
Gj/G0 protein-coupled receptors composed of a single polypeptide chain with an 
extracellular N-terminal domain (see Fig 1.2.4.1.), 7TM helical domains connected by 
three extracellular and three intracellular loops and an intracellular C-terminal tail. On the 
basis of the 2.8 A resolution 3-D structure of rhodopsin [106], it is assumed that the 7TM 
helices of opioid receptors are arranged sequentially in a counterclockwise fashion 
forming a tight helical bundle. Together with the extracellular domains of the receptor, 
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this provides a dynamic interface for the binding of various opioid ligands. Opioid 
receptors are about 60%-70% identical to each other with the greatest homology in the 
TM helices, the intracellular loops, and a portion of the C-terminal tail adjacent to the 
TM7 domain and the greatest diversity in their N- and C-termini as well as their 
extracellular loops [23]. In addition, all three opioid receptors possess two conserved 
cysteine residues in the first and second extracellular loops, which probably form a 
disulfide bridge. The TM2 and TM3 contain conserved aspartate residues [152], which 
are believed to form an ion pair with the positively charged nitrogen atom, which is a 
strict structural requirement common to all opioid ligands [98]. These conserved aspartic 
residues play a role in morphine and enkephalin binding in TM3 [13]. The third 
intracellular loop has been implicated in the binding of G-proteins, and the high 
homology at this portion of the receptor suggests that various opioid receptors interact 
with similar G-protein complexes. The third intracellular loop also has consensus 
sequences for phosphorylation, which might be involved in regulatory processes. At the 
N-termini, consensus sites are present for N-linked glycosylation, though the different 
opioid receptors have different number of glycosylation sites [66]. 
Many ligands act promiscuously on p.-, 5-, K-receptors, yet there are selective 
ligands for each receptor. On the basis of mutational analysis, chimeric receptor studies, 
and computational modeling, it is evident that opioid receptors have some common 
features defining an opioid-binding pocket and more divergent aspects that delineate high 
affinity and selectivity for receptor type-specific ligands [124, 119, 75, 21]. It has been 
suggested that all opioid receptors share a common binding cavity that is situated in an 
inner interhelical conserved region comprising T M helices 3, 4, 5, 6, and 7. This cavity is 
partially covered by the extracellular loops. These highly divergent extracellular loops, 
together with residues from the extracellular ends of the TM segments, play a role in 
ligand selectivity, especially for peptides, allowing them to discriminate between the 
different opioid receptor types [119]. Agonist ligand selectivity for p.-, 8-, K-receptors has 
been attributed to the first and third extracellular loop for the g-receptor [21, 104, 88, 
160], the second extracellular loop for the K-receptor [167], and the third extracellular 
loop for the 8-receptor [163]. 
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Fig.1.2.4.1. Schematic representation of the human p-opioid receptor. Amino acids 
conserved between human p.-, 5- and K-receptors are indicated in red. Transmembrane 
domains are numbered. [78] 
1.2.5 Oligomerization of opioid receptors 
1.2.5.1. Opioid receptor homo-oligomers 
Using Western blot analysis of heterologous cell expression systems, 
immunoreactive bands corresponding to monomers, dimers, and higher-order oligomers 
for the p- [41], 5- [41, 61, 43], and K- [61] opioid receptors have been demonstrated. 
Opioid receptor oligomerization has significant potential implications in therapeutic drug 
design because ligands that interact with multiple receptors simultaneously may be more 
efficacious. 
1.2.5.2. Hetero-oligomerization between opioid receptors 
6-K-opioid receptor hetero-oligomers 
The S-K-opioid receptor heterodimer has an altered ligand-binding profile: K-
receptor selective agonists (U-69593, dynorphin A) and antagonists (norBNI) and 5-
receptor selective agonists (DPDPE) and antagonists (TIPPv|/, BNTX) have decreased 
affinity, whereas non-selective opioid receptor antagonists (naloxone, diprenorphine) 
have an increased affinity [61], The 5-K-opioid-receptor heterodimer displayed novel 
signaling and regulatory properties. A synergistic inhibition of adenylyl cyclase activity, 
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and a marked increase in MAPK phosphorylation was evident following cotreatment with 
8- and K-receptor selective ligands [61]. 
p-8-opioid-receptor hetero-oligomers 
Differentially epitope-tagged u- and 8-opioid-receptor also coImmunoprecipItated 
from COS cells [41]. A novel-binding site was revealed by an altered rank order of 
potency: selective agonists (DADLE, DPDPE, DAMGO, morphine) had a reduced 
affinity whereas the endogenous opioid peptides endomorphin-1 and Leu-enkephalin had 
an increased affinity [41]. In contrast to individually expressed receptors, coexpressed p-
and 8-opioid-receptor displayed insensitivity to both GTPyS and PTX [41] 
1.2.5.3. He te ro-o l igomer iza t ion between opioid receptors a n d o ther G P C R s 
Recent studies show that 5- and K-receptors interact with the (^-adrenoceptor [62], 
1.2.6. E f fec to r M e c h a n i s m s 
The opioid receptor family belongs to the Gi/G0-coupled superfamily of receptors. 
It seems likely that all of the opioid receptors will share common effector mechanisms. 
Given the heterogeneity of a„ a0, (3 and y subunits which may form a trimeric G-protein, 
there may be some subtle differences in the downstream effector mechanisms to which 
opioid receptors are coupled if one type of opioid receptor is unable to interact with a 
certain form of G,/G0 heterotrimer. Opioid receptor activation produces a wide array of 
cellular responses (Table 1.2.6.1.). 
Table 1.2.6.1. Opioid receptor-evoked cellular responses [26] 
Direct G-protein Py or a subunit-mediated effects 
• Activation of an inwardly rectifying potassium channel 
• Inhibition of voltage operated calcium channels (N, P, Q and R type) 
• Inhibition of adenylyl cyclase 
Responses of unknown intermediate mechanism 
• Activation of PLA 
• Activation of PLCP (possibly G protein Py subunit activation) 
• Activation of MAPKinase 
• Activation of large conductance calcium-activated potassium channels 
• Activation of L type voltage operated calcium channels 
• Inhibition of T type voltage operated calcium channels 
• Direct inhibition of transmitter exocytosis 
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1.3. Opioid Ligands 
1.3.1. Endogenous opioid ligands 
In mammals the endogenous opioid peptides are derived from three precursors: 
proopiomelanocortin (POMC), pro-enkephalin, pro-dynorphin [100, 63, 103]. Active 
peptides derived from these precursors all have the pentapeptide sequence 
TyrGlyGlyPheMet/Leu at their N-termini. These peptides vary in their affinity for p, 8-
and K-receptors, but none bind exclusively to one opioid receptor type [87]. The 
exceptions are endomorphin-1 and endomorphin-2 [175], they are putative products of a 
yet unidentified precursor and they have been proposed to be the endogenous ligands for 
the p-receptor. Endomorphins are C-terminally amidated tetrapeptides and are 
structurally unrelated to the other endogenous opioid peptides (Table 1.3.1.). POMC 
gives rise to endorphins, and the non-opioid ACTH and MSH [85], Proenkephalin 
contains one copy of Leu-enkephalin, four copies of Met-enkephalin and two copies of 
the extended Met-enkephalins. Prodynorphin gives rise to dynorphin A and B, and a-, [3-
neoendorphins. The neuroactive peptides are situated towards the C-terminal of the 
polypeptide precursor. The neuroactive domains of the precursors are marked by pairs of 
basic amino acid residues that form potential cleavage sites for trypsin-like enzymes. It is 
found that the same precursor protein is present in several different tissues, but undergoes 
different post-translational processing. It seems likely that the differences in the four 
precursor proteins arise from differences in the splicing of mRNA chains after the 
excision of introns [138]. 
Amphibian skin contains two families of D-amino acid-containing peptides that 
are p.- or 8-receptor selective. Dermorphin is a p-selective heptapeptide [97], In contrast, 
the deltorphins: deltorphin (dermenkephalin), [D-Ala2]- deltorphin I and [D-Ala2]-
deltorphin II are highly selective for 8-receptors [32]. Dermorphins contain an N-terminal 
tripeptide sequence Tyr-D-Xaa-Phe that is also present in deltorphins. This common 
sequence motif which is topologically distinct from the region (C-terminal 'address' 
domain of the ligands) ensuring site-specific interactions with the receptors is recognized 
by both p- and 8-opioid receptors [20]. By contrast, the endogenous mammalian opioid 
peptides are characterized by an identical N-terminal 'message' tetrapeptide sequence 
Tyr-Gly-Gly-Phe [122], endomorphins are exceptions. 
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Table 1.3.1. Structure of endogenous opioid peptides 
Opioid peptides Structure Precursor 
p-endorphin YGGFMTSEKSQTP LVTLFKN 
A I I K N A Y K K G E 
POMC 
Met-enkephalin Y G G F M Proenkephalin 
Met-enkephalin-Arg6-Phe7 YGGFMRF 
Met-enkephalin-Arg6-Gly7-Leu8 Y G G F M R G L 
Leu-enkephalin YGGFL 
dynorphin A (1-17) YGGFLRRIRPKLKWDNQ Prodynorphin 
dynorphin B Y G G F L R R Q F K V V T 
a-neo-endorphin Y G G F L R K Y P K 
P-neo-endorphin Y G G F L R K Y P 
dermorphin YaFGYPS-NH2 Frog skin peptides 
deltorphin (dermenkephalin) YmFHLMD-NH2 
[D-Ala2]deltorphin-l YaFDVVG-NH 2 
[D-Ala2]deltorphin-II Y a F E W G - N H 2 
endomorphin-I YPWF-NH2 Unknown 
endomorphin-II YPFF-NH2 
1.3.1.1. Met-enkephalin-Arg6-Phe7 
Met-enkephalin-Arg6-Phe7 (Tyr-Gly-Gly-Phe-Met-Arg-Phe; MERF) is a naturally 
occurring heptapeptide derived from the precursor polypeptide proenkephalin A [148]. 
MERF is localized at the C-terminus within the prepropeptide structure and its sequence 
is well conserved among mammalian species. It was first isolated from bovine adrenal 
medullary granules and striatal extracts [147], and later from molluscan neural tissue 
[77], hagfish, lampray [30], amphibian [68], reptile [80], rat and human brain tissue [118, 
127, 155], A different heptapeptide structure at the homologous position of the precursor, 
Met-enkephalin-Gly-Tyr has recently been deduced from zebrafish proenkephalin 
cDNAs [44], There are age-related and diurnal changes in MERF contents depending on 
rat brain structures [155]. Antinociceptive [56] and antitussive effects of the peptide have 
been reported in mice [64], all of which were sensitive to naloxone antagonism, 
indicating that MERF exerts its pharmacological action through opioid receptors. MERF 
has also produced cardiovascular effects such as vasodepression and bradycardia [31] in 
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rats, and it seemed to be involved in immunity, by stimulating immunocytes [146] and 
the release of proinflammatory cytokines, e.g. interleukine-6 [178], The heptapeptide 
may be associated with the ability to control the aggressive reaction in rats treated with 
nandrolone decanoate [58]. Opioid receptor binding properties of MERF have been 
reported in various species using radiolabeled alkaloid compounds [ H]etorphine and 
[3H]ethylketocyclazocine [5, 6, 11, 45], From these experiments it was concluded that the 
heptapeptide binds preferably to K2-opioid receptors [170], According to early definition, 
K2-opioid sites are sensitive to D-At -D-Lei -enkephalin [5, 6, 135], moreover they 
exhibit a binding preference for benzomorphans over arylacetamides [12, 181], and are 
characteristically localized throughout the brain [161]. A tritiated analogue of MERF was 
"i 
previously prepared in our laboratory [171], [ HJMERF has been shown to label opioid 
(k2 and 8) sites in rat and frog brain membrane preparations [14] and it also binds to non-
opioid sites in rat and guinea-pig cerebellum and forebrain [15]. Pentapeptide- and C 
terminally elongated enkephalins were reported to be sensitive to enzymatic degradation 
by peptidases [3, 51], so selective inhibitors should be added to prevent decomposition of 
the peptide ligands. Methionine in the fifth position can also be susceptible to oxidation. 
To increase the stability and to overcome the problem of oxidation and to gain structure-
activity relationship information, several new MERF analogues with D-amino acid 
substitutions were synthesized and tested in radioligand-hinding assays as well as in in 
vivo pharmacological tests. Replacement of Gly2 for D-Ala2 results in inhibition of 
cleavage in the first peptide bond, protecting Tyr1, which is essential for opioid activity. 
Methionine in the fifth position (Met5) was replaced with its isosteric amino acid, 
norleucine (Nle), utilizing both L-Nle5 and D-Nle1 substitutions. A novel analogue 
containing double D-amino acid substitutions at the second and fifth position, Tyr-D-Ala-
Gly-Phe-D-Nle-Arg-Phe, abbreviated as DADN exhibited changes in ligand-binding 
pattern when compared to the parent heptapeptide. In binding assays using [3H]MERF 
and ['Hjnaloxone, lower affinities were observed for DADN compared to the natural 
structure. On the other hand, the new ligand showed substantially higher affinity toward 
p-binding sites as measured by [ TJDAMGO [laboratory observations]. The 
pharmacological experiments clearly demonstrated that icv. administered D A D N has a 
profound, naloxone-sensitive analgesic effect on freely moving rats [153]. 
13 
1.3.2. Synthetic opioid ligands 
1.3.2.1. 14-Methoxymetopon 
p-Opioids (morphine, methadone, fentanyl and oxycodone) represent the major 
class of strong analgesics used clinically. Despite their profound utility in the 
management of pain, they have a number of adverse side effects, such as respiratory 
depression, constipation, sedation, tolerance and addiction [84], that impede their overall 
utility. This has led to an active search for novel opioid compounds exhibiting a 
favourable dissociation between analgesic activity and the development of 
dependence/tolerance and other side effects. 
A derivative of the 14-alkoxymorphinan series [132], 14-methoxymetopon (4,5a-
epoxy-3-hydroxy- 14[3-methoxy-5(3,17-dimethylmorphinan-6-one, Fig. 1.3.2.1.) appears 
to be a potent and selective-agonist, which exhibits an analgesic action far more potent 
than morphine (300-20,000-fold, depending upon the assay used) in diverse nociceptive 
tests (tail flick, hot plate, acetic acid-induced abdominal constriction test) [132, 39, 180, 
69] in rats and mice. The dependence liability of the compound in the withdrawal 
jumping test is less pronounced than that of morphine in rats and mice [39], Moreover, 
compared with sufentanil, 14-methoxymetopon elicits a slight respiratory depression, it 
does not induce hypoxia and hypercarbia, it produces less hypotension, bradycardia and it 
produces less sedative effects in the dog [37]. Recently, 14-metoxymetopon has been 
reported as being far more effective than morphine in reducing the emotive/affective 
component of pain (measured by vocalization responses to tail electric stimulation test) 
and in producing an anxiolytic effect (measured by plus-maze test). In addition, it 
increased the serum corticosterone levels and the hypothalamic serotonin content. A 
possible correlation between the anxiolytic action of the drug and its effect on the 
hypothalamic serotonergic system was also suggested [162], The enhanced potency of 
14-methoxymetopon is increased with either spinal or supraspinal administration, where 
its analgesic activity is more than a million-fold greater than morphine. It showed 
approximately 3-fold greater affinity for p ropioid binding sites (using [3H]DADLE in 
the presence of DPDPE) than p2-opioid sites (using [3H]DAMGO in the presence of 
DSLET) in competition binding assays performed in calf thalamus membrane 
preparations. The analgesic effect of the ligand was blocked only by p-opioid receptor 
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selective antagonists (naloxonazine and P-funaltrexamine), and it retarded gastrointestinal 
transit [69]. To establish the specificity of the ligand competition experiments were 
performed with highly selective radioligands: [3H]DAMGO, [3H]DSLET, [3H]U69,593. 
The highest affinity was for the p-sites (Kj=0.33±0.05nM) [39], In rat brain membranes 
[3H]14-methoxymetopon specifically labeled a single class of opioid binding sites with a 
K<i value of 0.43nM. An extremely low nonspecific binding (<10%) was observed in 
binding experiments. In competition binding assays using [3H]14-methoxymetopon, p-
opioid receptor ligands: 14-methoxymetopon, levorphanol, morphine, DAMGO, 
endomorphin-1, endomorphin-2, and nonselective naloxone showed affinities in the 
subnanomolar or low nanomolar range (Kj=0.48-6.99nM). Selective K-opioid compounds: 
norBNI and U69,593, and 5-opioid ligands: [Ile5'6]-deltorphin and HS 378 were found to 
be weaker inhibitors of [3H]14-methoxymetopon binding (Kj=38.8-528nM) [143]. A 
higher number of binding sites were labeled by [3H]14-methoxymetopon (314 fmol/mg 
protein) in rat brain membranes compared to other p-opioid receptor radioligands: 
[3H]dermorphin [2], [3H]TAPP [141], and [3H]cyprodime [89], Being a nonpeptide 
ligand, [3H]14-methoxymetopon has the clear advantage of increased stability compared 
to opioid peptides, such as [ H]endomorphin-2, which has been described to be sensitive 
to enzymatic degradation during binding conditions [140], 
The in vitro agonist property of 14-methoxymetopon was proven by showing a 
sodium index of 41 that indicates high agonist potency. The ligand also exhibited a potent 
agonistic action on isolated electrically stimulated GPI preparation (it induced a 
concentration-dependent, naloxone reversible inhibitory effect, 72.4 times more potent, 
than normorphine) [39], Thus, 14-methoxymetopon appears to be a very promising 
compound that has high analgesic potency and considerably less pronounced adverse side 
effects than other opioid compounds used in therapy at the moment. 
Fig. 1.3.2.1. The chemical structure of 
14-methoxymetopon. 
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2. AIM OF THE STUDIES 
Despite the big progress made in opioid research, further studies are needed to 
understand the mechanisms of action of opioid receptors. The development of new, 
highly selective ligands and investigation of the reasons underlying their selectivity is one 
of the ways leading to the full comprehension of the problem. p-Opioids represent the 
major class of strong analgesics used clinically. The present study was dedicated to 
biochemical and functional analysis of opioid ligands acting at the p-opioid receptor. The 
studied ligands include synthetic (heterocyclic) and modified endogenous compounds 
(peptide). 
In the first part ['IfjTyr-D-Ala-Gly-Phe-D-Nle-Arg-Phe, an analogue of the naturally 
occurring Met-enkephalin-Arg6-Phe was biochemically analysed. The main goals were: 
• To have a novel opioid ligand with improved stability and specificity. 
• To measure its opioid activity in kinetic, equilibrium and competition binding studies. 
• To compare its opioid binding properties with those of other well-known compounds 
labeling opioid receptors. 
• To test if this compound is able to generate the intracellular response characteristic to 
opioids (G protein activation). 
• To test if this effect is p-opioid receptor selective (reversibility by a p-antagonist). 
• Determination of the agonist/antagonist character of the compound. 
In the second part a derivative of the 14-alkoxymorphinan series, 14-methoxymetopon 
was analysed functionally. The main goals were: 
• To test if this compound is able to generate the intracellular response characteristic to 
opioids (G protein activation). 
• To test if this effect is p-opioid receptor selective (reversibility by a p-antagonist). 
• Determination of the agonist/antagonist character of the compound. 
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3. MATERIALS AND METHODS 
3.1. Chemicals 
3.1.1. Radiochemicals 
Tritiated naloxone (72 Ci/mmol) was synthesised in the Isotope Laboratory of 
BRC, Szeged, Hungary. Guanosine-5'-[y-35S]-triphosphate (1000-1300 Ci/mmol) was 
purchased from the Isotope Institute Ltd. (Budapest, Hungary). [3H]Tyr-D-Ala-Gly-Phe-
D-Nle-Arg-Phe (41 Ci/mmol) was prepared by catalytic dehalogenation of its precursor 
peptide [159]. 
3.1.2. Opioid peptides 
D A M G O was purchased from Bachem Feinbiochemica, Bubendorf, Switzerland. 
DADN, MERF, D-Ala2-MERF, TIPP [159, 171], endomorphin-1, endomorphin-2, Met-
enkephalin and Ile5,6-deltorphin II were prepared by solid phase peptide synthesis in the 
Isotope Laboratory, Szeged, Hungary [115, 102], C T A P was provided by Multiple 
Peptide Systems (San Diego, Ca, USA). 
3.1.3. Synthetic alkaloids 
Naloxone was from Endo Labs (Garden City, NJ, USA). NorBNI and naltrindole 
were from ICN-Hungary (Tiszavasvari, Hungary). Bremazocine and ethylketo-
cyclazocine were from Sterling-Winthrop (Rensselaer, N Y , USA). Dextrorphan and 
levorphanol were purchased from Hoffmann-La Roche (Nutley, NJ, USA). U-69,593 was 
obtained from Upjohn Company (Kalamazoo, Michigan, USA). Morphine and 
buprenorphine were from ICN-Hungary Co., Tiszavasvari, Hungary. 14-
Methoxymetopon, HS378 and cyprodime were kindly provided by Dr. H. 
Schmidhammer (University of Innsbruck, Innsbruck, Austria). 
3.1.4. Other Chemicals 
All other chemicals used in this study were of analytical grade. 
3.2. Animals 
Inbred Wistar rats (250-300 g body weight) were housed in the local animal house 
of the Biological Research Center (Szeged, Hungary). Rats were kept in-groups of four, 
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allowed free access to food and water and maintained on a 12/12-h light/dark cycle until 
the time of sacrifice. Animals were treated according to the European Communities 
Council Directives (86/609/EEC) and the Hungarian Act for the Protection of Animals in 
Research (XXVIII.tv. 32.§). 
3.3. Membrane preparations 
3.3.1. Preparation of rat brain membranes 
A crude membrane fraction was prepared from Wistar rat forebrains according to 
a method of Pasternak with small modifications [14]. Two-three month-old animals were 
decapitated, and the brains without cerebella were rapidly removed, and washed several 
times with chilled 50 mM Tris-HCl buffer (pH 7.4). The brains were weighed and 
suspended in 5 vol/wt of brain tissue of the ice-cold buffer. Tissues were homogenized 
using a Braun teflon-glass homogenizer (1000 rev./min, 10-15 strokes), and filtered 
through four layers of gauze to remove large aggregates. Additional buffer was added to 
reach a final buffer volume/membrane pellet ratio of 30 (ml/g). After centrifugation with 
a Sorvall RC5C centrifuge (40000x g, at 4°C, for 20 min), the resulting pellet was 
resuspended in fresh buffer (30 vol/wt) by using a vortex. The suspension was incubated 
at 37°C for 30 min to remove any endogenous opioids. Centrifugation was repeated 
under the same conditions as described above, and the final pellet was resuspended in 5 
volumes of 50 mM Tris-HCl buffer (pH 7.4) containing 0.32 M sucrose to give a final 
protein concentration of 3-4 mg/ml. The membrane samples were stored in 5 ml aliquots 
at -70°C. The protein concentration was determined by the Bradford method [18]. 
Before use the membranes were thawed and resuspended in 50 mM Tris-HCl buffer (pH 
7.4) and centrifuged (40000x g, 4°C, 20 min) to remove sucrose and used immediately. 
3.3.2. Membrane preparation from C H O Ô , C H O K and CHOp cell cultures 
Chinese hamster ovary (CHO) cells stably transfected with p.-, 8- or K-opioid 
receptors (CHOp, C H O Ô and C H O K cells) were grown in Dulbecco's modified Eagle's 
medium (DMEM, Gibco) and in a-minimum essential medium (aMEM, Gibco), 
respectively. Both media were supplemented with 10% fetal calf serum, 2 mM glutamine, 
100 IU/ml penicillin, 100 mg/ml streptomycin, 25 mg/ml fungizone and 0.5 mg/ml 
geneticin. Cells were maintained in culture at 37°C in a humidified atmosphere consisting 
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of 5% C0 2 and 95% air. Membranes were prepared from subconfluent cultures. Cells 
were rinsed three times with 10 ml PBS and removed with 50 mM Tris-HCl pH 7.4, 1 
mM EGTA, 1 mM EDTA and 0.1 mM PMSF buffer and homogenized for 15 sec with a 
polytron homogeniser in an ice-bath. Homogenates were centrifuged two times at 
18,000xg for 20 min. The final pellet was resuspended in the above buffer containing 0.3 
M sucrose and stored in aliquots at -70°C until use. 
3.4. Radioligand binding assays 
3.4.1. Theoretical basis 
Radioligand binding is a technique that measures the binding of a labeled ligand 
to its receptor. Receptor binding studies are used to determine the affinity (Kd) of various 
drugs for a receptor as well as the binding site density (Bmax) of receptor families in 
different tissues. The technique can also be adapted to study the association and 
dissociation kinetics of ligand binding, and complex allosteric interactions between 
receptors and effector molecules, such as G proteins. There is a requirement for a high-
affinity radioligand for the receptor being studied, low affinity for other receptors and a 
high specific radioactivity. Two basic types of assays utilize radioligands: direct b inding 
assays measure the direct interaction of a radioligand with a receptor; indi rect b inding 
assays measure the inhibition of the binding of a radioligand by an unlabeled ligand. 
Analysis of radioligand binding experiments is based on a simple model, called 
the law of mass action: the basis of the receptor binding study is the binding of ligand (L) 
to the receptor (R) to form a ligand-receptor complex (LR). The ligand-receptor complex 
is classically referred to as Bound, meaning the amount of ligand that is bound to the 
receptor. The unbound ligand (L) is referred to as Free, meaning the amount of ligand 
that is free and able to interact with the receptor. The parameter measured is the amount 
of radioactive ligand that is bound to the receptor. This requires separation of the free 
ligand from the bound ligand after the reaction has reached steady-state conditions. Once 
steady-state conditions have been reached, the bound radioactive ligand is separated from 
the free ligand using filtration. The filtration method functions by trapping the receptor-
ligand complex on the filter, whilst allowing the free ligand to pass through. The amount 
of receptor-ligand complex formed (Bound) can be estimated by measuring the amount of 
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radioactivity on the filter. In our experiments we used a Brandel M-24 cell harvester-type 
filter machine for filtering tissue homogenates. If binding of the radioligand to the filter is 
too high, the filter can be soaked in 0.1% PEI solution. 
The amount of radioactive ligand bound can be determined using a liquid 
scintillation counter. For our measures we used a Packard TriCarb 2300TR Liquid 
Scintillation Analyzer. The filter is simply placed in a counting vial and scintillation fluid 
is added. 
Equilibrium is reached when the rate at which new ligand'receptor complexes are 
formed equals the rate at which the ligand'receptor complexes dissociate. At equilibrium: 
[Ligand]* [Receptor] 'kon = [Ligand'Receptor]'koff 
Where kon: is the association rate constant in units of M 1 min 1 
k0ff: is the dissociation rate constant in units of mnf 1 
Once ko,, and kon- have been seperately determined in kinetic experiments we can 
rearrange the equation to define the equilibrium dissociation constant K g 
[Ligand]'[Receptor]/ [Ligand'Receptor] = k0n/k0n=-- K 
Kd is the concentration of the ligand, which will occupy half of the available receptors at 
equilibrium. If binding follows the law of mass action, the K calculated this way should 
be the same as the Kd calculated from a saturation experiment. 
Scatchard plots (more accurately attributed to Rosenthal) are most often used to 
linearize binding data [130]. In this transformed plot, the X-axis is specific binding 
(usually labeled "bound") and the Y axis is the ratio of specific binding to concentration 
of free radioligand (usually labeled "bound/free"). Bmax is the X intercept; Kd is the 
negative reciprocal of the slope. K is calculated from a saturation binding experiment 
using the Scatchard formula: [B]/[F]= (Bmax-fB])/^ 
where [B] is the specifically bound ligand, [F] is the total free concentration of the ligand, 
Bmax is the maximum number of binding sites, Kd is the equilibrium dissociation constant. 
When analysing a competitive binding experiment we want to determine the 
inhibitory constant: Kg The K; value for the unlabeled ligand can be obtained from the 
IC5o value using the Cheng-Prusoff equation [25] where [L] is the concentration of 
radioactive ligand used and Kd is the affinity of the radioactive ligand for the receptor. 
K p IC 5 o / ( l+ [L] /Kd) 
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3.4.2. Receptor binding assay 
The membrane suspensions from rat brain were incubated in polypropylene assay 
tubes for 30 min at 24°C with the radioligand in a final volume of 1 ml. Incubations were 
carried out in 50 mM Tris-HCl buffer (pH 7.4) containing 1 mM EDTA, 0.1 mM PMSF, 
20 pg/ml bacitracin, 40 KlU/ml trasylol and 1 mg/ml protease free BSA. Incubation was 
started by the addition of membrane suspension and terminated by rapid filtration 
through Whatman GF/C glass fiber filters presoaked in 0.3% PEI at pH 10, using a 
Brandel M24R Cell Harvester. After three washings with 5-ml portions of ice-cold 
buffer (50 mM Tris-HCl, 5 mM KC1, 2 mM MgCl2, 0.1 mg/ml BSA, pH 7.4) filters were 
dried for 3 h at 37°C. The radioactivity was measured in a toluene-based scintillation 
cocktail, using a Packard TriCarb 2300TR spectrophotometer with 58% counting 
efficiency. Potencies of competing ligands were determined by co-incubation with 10 ! l-
10 4 M freshly prepared solutions of the unlabeled drugs with 0.5-1 nM tritiated ligand. 
Non-specific binding was defined as the radioactivity bound in the presence of 10 pM 
unlabeled DADN or naloxone. All assays were performed in duplicate and repeated 
several times. Experimental data were analyzed by the GraFit, a non-linear least-squares 
curve fitting programme [76] or with GraphPad Prism [145], Data are generally 
expressed as arithmetic means ± SEM of at least three repeated assays. 
3.5. Determination of protein concentration: 
The protein concentration was determined by the method of Bradford [18], 
3.6. In vivo (pain test 
For spinal drug administration, rats were surgically prepared under ketamine-
xylazine anesthesia (72 and 8 mg/kg intraperitoneally, respectively). An intrathecal 
catheter (PE-10 tubing) was inserted through a small opening in the cisterna magna and 
passed 8.5 cm caudally into the intrathecal space. Fixation of.the cannula was performed 
according to Yaksh et al. [173]. After surgery, the rats were housed individually, had free 
access to food and water, and were allowed to recover for at least 4 days before use. Rats 
exhibiting postoperative neurologic deficits (<10%) were not used. All experiments were 
performed during the same period of the day (8:00 A M to 1:00 PM) to exclude diurnal 
variations in pharmacological effects. The animals were randomly assigned to treatment 
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groups, and the observer was blind to the treatment administered. Acute nociceptive 
sensitivity was assessed by using the tail-flick test. The reaction time in the tail-flick test 
was determined by immersing the lower 5 cm portion of the tail in the hot water until a 
tail-withdrawal response was observed (51.5°C water, cut-off time: 20s). Baseline 
latencies were obtained immediately before and then 10, 30 and 60 min after the drug 
injections. Animals given physiological saline were used as control. Analgesic latencies 
in acute pain tests were converted to the percent maximal possible effect (%MPE) by 
using the following formula: 
%MPE=([observed latency - baseline latency]/[cutoff - baseline latency])* 100. 
Experimental paradigms were as follows: 
i/ Dose-response curve for DADN: 
The first series of experiments were performed to determine the dose-response and time-
course for intrathecally administered DADN. In a further series we compared the 
antinociceptive potency of DADN with the parent compound (MERE, 100 nmol) and a 
•j 
monosubstituted derivative (D-Ala -MERE, 100 nmol). 
ii/ Antagonism of DADN effect: 
The second series of experiments were performed to antagonize the antinociception with 
different opioid receptor antagonists. The ji-opioid receptor specific naloxone (1 and 10 
nmol), the S-receptor selective naltrindole (1 nmol) or the K-receptor selective norBNI, (1 
nmol) was coadministered with 10 nmol DADN. 
3.7. GTPyS binding assay 
3.7.1. Theoretical basis 
Agonist stimulated [35S]GTPyS binding assay is a functional test that measures 
the increase in guanine nucleotide exchange at G proteins in cell membranes, resulting 
from agonist binding to GPCRs, by monitoring the binding of a radiolabeled, hydrolysis-
resistant analogue of GTP, [35S]GTPyS, in the presence of unlabeled GDP. In the resting 
state, the a subunit of the G protein is bound to GDP. Activation of the receptor by an 
agonist leads to the dissociation of GDP from the G protein, allowing GTP to bind [42], 
This leads to the dissociation of the a and (3y subunits of the G protein, which are then 
able to interact with effector systems. The binding of [35S]GTPyS has been previously 
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used to provide a measure of G protein activation by agonists [83], This assay is useful 
for determining the relative efficacies of p-opioid agonists in vitro, using exogenous 
drugs that have been well characterized [158]. The correlation between the intrinsic 
activity of a drug in this assay and its efficacy in vivo makes it an appropriate system for 
measuring the relative efficacies of opioids. 
3.7.2. Experimental design 
Rat brain membranes (-10 pg of protein/ tube) were incubated for 60 min at 30°C 
in Tris-EGTA buffer (50 mM Tris-HCl buffer, 3 mM MgCl2, 1 mM EGTA, 100 nM 
NaCl, pH 7.4) containing 0.05 nM [35S]GTPyS with increasing concentrations (10"10-10~5 
M) of opioid ligands tested in the presence of 30 pM GDP in a final volume of lml. 
Basal activity was determined by subtracting the non-specific binding (measured in the 
presence of 100 pM unlabeled GTPyS) from the total binding (measured in the absence 
of tested compounds). The incubation was started by the addition of [35S]GTPyS and was 
terminated by vacuum filtration through Whatman GF/B glass fibre filters. Filters were 
washed three times with ice-cold 50 mM Tris-HCl buffer (pH 7.4) and then dried. The 
bound radioactivity was measured in a toluene-based scintillation cocktail, using a 
Packard TriCarb 2300TR Liquid Scintillation Analyzer. Stimulation is given as 
percentage of the basal activity. Data were calculated by fitting sigmoid dose-response 
curves using the GraphPadPrism program [145], 
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4. Results 
4.1. Biochemical characterization of [3H]Tyr-D-Aia-Gly-Phe-D-Nle-Arg-Phe 
4.1.1. Checking the stability of the radiolabeled compound [3II]DADN 
Tyr-D-Ala-Gly-Phe-D-Nle-Arg-Phe (DADN) was prepared in unlabeled as well as 
in tritiated form. The labeled peptide ligand, [3H]DADN exhibited a specific radioactivity 
of 41 Ci/mmol, and is shown as a single peak on the HPLC radiochromatogram. The 
integrity of the radiolabeled peptide was checked after incubating with rat brain 
membranes to verify the stability of the ligand. Enzymatic resistance of [3H]DADN was 
determined under standard assay conditions, same as in the equilibrium binding 
experiments. The following peptidase and proteinase inhibitors were included in the 
reaction mixture: 1 raM EDTA, 0.1 mM PMSF, 20 pg/ml bacitracin, and 40 KlU/ml 
trasylol. The relatively good recovery of the radiolabeled peptide confirms that no 
significant degradation has occurred when peptidase blockers were present, indicating an 
intrinsic resistance of the ligand. in the absence of specific inhibitors basically the same 
pattern was found (Figures not shown). 
4.1.2. Determination of appropriate conditions for equilibrium binding studies with 
[3HJDADN 
To determine appropriate conditions for equilibrium binding studies of 
[3H]DADN, the temperature dependence was first studied. Specific binding and 
specific/non-specific binding ratio of [ H]DADN at 0°C, 35°C and 37°C was much less 
than at room temperature (data not shown), therefore all subsequent binding experiments 
were conducted at 24°C. 
4.1.3. Kinetic experiments 
Time-dependence of binding interaction was examined by incubating the rat brain 
"i 
membrane preparations with [ HjDADN until reaching equilibrium. Dissociation was 
then initiated by adding 10 pM unlabeled DADN or naloxone. Kinetic studies revealed 
relatively rapid, monophasic association with pseudo-first order kinetics (Fig. 4.1.2., left 
panel). Non-specific binding remained unchanged within the time intervals tested. Only 
specific binding data are shown. Steady-state condition was reached in 30 min with 
[3H]DADN at 24°C. Dissociation of the receptor-radioligand complex followed first 
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order kinetics (exponential decay, Fig. 4.1.2., right panel). The association rate constant 
(k+i) was 0.162 min'nM"1 and the dissociation rate constant (k_i) was 0.1782 min"1. A 
'kinetic' dissociation constant (K<i) of 1.1 nM was derived from these rate constant values 
(Kd= k.i/k«.i). 
Association time (min) Dissociation time (min) 
Fig. 4.1.2. Association and dissociation kinetics of [3H]DADN binding. Membranes from 
rat brain were incubated with 0.45 nM [ H]DADN for various time intervals. 
Dissociation was initiated by addition of 10 pM unlabeled DADN at the steady state. 
Points represent means ± SEM of at least three experiments, carried out in duplicates. 
4.1.4. Saturation experiments 
In the equilibrium saturation experiments, various concentrations (0.05-16 nM) of 
the radioligand were incubated with the membrane. Binding of [3H]DADN to rat brain 
membranes at 24°C was saturable and of high affinity. The equilibrium dissociation 
constant (IQ), which measures the affinity of a ligand for a receptor and the maximal 
number of binding sites (Bmax) were calculated by non-linear regression analysis of the 
saturation binding data (Fig. 4.1.3.). The results showed the existence of a single binding 
component with a Kj value of 2.1 ±0.1 nM, which is similar with the IQ obtained from 
the kinetic experiments. The binding capacity (Bmax) was 72 ± 13 fmol/mg protein, a 
value that agrees well with the reported number of p-opioid receptor sites in rat brain [89, 
2, 141]. Non-specific binding of [ H]DADN to rat brain membrane preparations was less 
then 30% of total binding at a radioligand concentration close to the K<t value. 
25 
Fig. 4.1.3 Saturation binding curve and Scatchard plot of [3H]DADN binding. Rat brain 
membranes were incubated with increasing concentration of [3H]DADN in the presence 
A ~~ " 
and absence of 10 pM naloxone for 60 min at 24°C. Each value represents the mean of a 
single experiments, carried out in duplicates and repeated several times with similar 
results. 
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4.1.5. Sodium index of DADN. 
Agonist/antagonist properties of the heptapeptide analogue was assessed using the 
well known in vitro effect produced by Na+ ions on opioid binding [114], Heterologous 
displacement experiments with [3H]naloxone (0.5-2 nM) and various concentrations of 
unlabeled DADN in the presence or absence of 100 mM NaCl were performed to 
evaluate its agonist/antagonist character (figure not shown). Sodium index value (Kj with 
Na+/Kj without Na+) was calculated to be 40.2 ± 9.2 nM, which suggested the agonist 
character of the peptide. 
4.1.6. Stereoselectivity of [3H]DADN 
Stereoselectivity of [3H]DADN binding sites was observed using optically active 
enantiomeric compounds (-)levorphanol and (+)dextrorphan in heterologous competition 
studies (Fig. 4.1.4.). The opiate agonist levorphanol presented high affinity (Kj value of 
0.3 nM) toward the [3H]DADN sites, whereas it's pharmacologically inactive 
dextrorotatory stereoisomer showed only very low affinity (Kj > 10 pM). 
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Fig. 4.1.4. Stereospecificity of [3H]DADN binding. Rat brain membranes were incubated 
for 30 min at 24°C with 0.45 nM [3H]DADN in the presence of increasing concentrations 
of levorphanol (A.) and dextrorphan (A). Each data point denotes the mean value of a 
duplicate experiment, representative of three others with similar results. 
4.1.7. Competition experiments by the use of various unlabeled ligands to displace 
bound [3H]DADN. 
The equilibrium competition experiments were performed by the use of various 
unlabeled ligands selective for p-, 8-, or K-opioid receptors to displace bound 
[3H]DADN. Several p-receptor selective compounds, including the specific agonist 
DAMGO, the selective antagonist cyprodime [131], the prototypic ligand morphine, the 
endogenous peptide agonists endomorphin-1 and endomorphin-2 [175], as well as 
levorphanol, competed for [3H]DADN binding sites in rat brain membrane preparations 
with much higher affinities than the 8-selective ligands: Ile5,6-deltorphin II [102], Met-
enkephalin and the k2/8 selective ligand MERF. Ligands selective for K-receptors: U-
69,593 and tifluadom displayed lower affinities. The data represented as equilibrium 
inhibition constant (Kj) values are shown in Table 4.1.1. 
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Table 4.1.1. Rat brain membranes were incubated for 30 min at 24°C with 0.5-1 nM 
[3H]DADN in the presence of increasing concentrations of opioid ligands. Values 
represent the mean ± SEM of 3-5 independent experiments performed in duplicate. 
Ligand Selectivity Kj (nM) 
D A D N p-agonist 4.3 ±0.6 
D A M G O p-agonist 4.8 ± 1.8 
Morphine p-agonist 6.8 ± 1.8 
Endornorphin-1 p-agonist 5.8 ± 1.9 
Endomorphin-2 p-agonist 3.9 ±0.8 
Cyprodime p-antagonist 10.6 ±4.6 
Naloxone General antagonist 1.4 ±0.3 
Buprenorphine partial p-agonist-K-antagonist 1.9 ± 0.8 
MERF K2/5-agonist 103.9 ± 4.1 
Ile5,6-deltorphin 11 5-agonist >3000 
Met-enkephalin 5/p-agonist 77.8± 13.1 
Ethylketocyclazocine Prototype K-agonist with p-antagonism 27.2 ± 5.9 
Tifluadom K-agonist 67.8 ±23 
U-69,593 Selective K-agonist >3000 
Bremazocine Non-selective agonist antagonist 1.3 ±0.2 
( - ) Levorphanol p-agonist 0.3 ± 0.06 
(+) Dextrorphan Inactive stereomer >10000 
4.1.8. Hot water tail-flick test 
Antinociceptive actions of different synthetic opioid peptides were measured on 
freely moving Wistar rats following intrathecal administration. Effect of DADN was 
compared to those of the parent compound (MERF) and a monosubstituted derivative, D-
Ala2-MERF. The dose -response curves showed that DADN. caused a dose-dependent 
antinociceptive potency in the tail-flick test (Fig 4.I.5.A.). Respiratory depression was 
also observed in some animals treated with 10 nmol DADN. The higher dose of DADN 
(100 nmol) caused serious respiratory depression, even death. As regards to the 
antinociceptive potency of the parent compound (MERF) and D-Ala2-MERF, both drugs 
exhibited only slight analgesic potency at a dose of 100 nmol (Fig. 4.1.5.B). The 
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coadministration of DADN with the different opioid receptor antagonists showed that the 
non-selective antagonist naloxone markedly decreased the antinociceptive effect 
generated by DADN. On the other hand, the 5-selective naltrindole and the K-selective 
antagonist norBNI did not significantly block DADN-induced antinociception (Fig. 
4.1.5.C). However, norBNI and DADN coadministration caused a significant 
hyperalgesia at 1 hour. The higher dose of naloxone (10 nmol) caused a more effective 
antagonism, showing a dose-dependent effect (Fig. 4.1.5.D) 
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Figure 4.1.5, Inhibition of acute thermal nociceptive responses by intrathecally 
applied opioid peptides in hot water tail-flick tests. The curves indicate the time-course 
effect of different doses of DADN (A), the antinociceptive effect of MERF and D-
Ala2-MERF (100 nmol/animal each) (B). Panel C shows the inhibition of 
antinociceptive effect of 10 nmol DADN by opioid antagonists (1 nmol/animal each). 
Panel D indicates the dose-dependent antagonism of DADN antinociception by 
naloxone. 
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4.1.9. Competition binding studies with DADN in rat spinal cord membranes 
The overall equilibrium binding affinity (Kj) calculated by homologous 
competition for [3H]DADN binding to rat brain membranes was found to be 4.3 ± 0.6 nM 
[159]. Because hot water tail-flick tests measure spinal reflexes, we also determined the 
binding of [3H]DADN to membranes prepared from spinal cord tissues of the rat. 
Homologous competition studies reveal specific, high affinity binding of the peptide to 
spinal recognition sites (Figure 4.1.6.). The K; value of unlabeled DADN in competing 
reversibly with [3H]DADN was 0.44 ± 0.045 nM, while the apparent number of the 
specific binding sites (Bmax) in spinal cord membranes was 72 ± 31 fmol/mg protein. 
Unfortunately the % of non specific binding was worse then in the case of rat brain 
membranes. 
[Ligand], (M) 
Figure 4.1.6. Competitive inhibition of [ H]DADN binding by unlabeled DADN in rat 
spinal cord membranes. Membrane preparations were incubated with 1.5 nM [3H]DADN 
for 30 min at 24°C in the presence of increasing concentrations of DADN. Points 
represent means ± SEM of three independent experiments each-performed in duplicates. 
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4.1.10. Homologous competitive binding experiments on CHO cell membranes 
Since the cloning of the three opioid receptor genes, by transfecting cells with the 
desired DNA, "purer systems" are available carrying only one type of receptor. This is a 
great advantage, since no matter how carefully an experiment is designed, when using 
brain membrane preparations a mixed receptor population is present, so the ambiguity of 
the results cannot be excluded. For this reason a set of experiments were carried out on 
membranes prepared from CHO (Chinese hamster ovary) cells transfected with cloned p-
, 8- and K-opioid receptors. As it was expected from the binding studies carried out on rat 
brain membranes, we detected high affinity ligand binding (IC50 in nanomolar range) in 
the CHO cells expressing p-receptors, while in the CHO cells expressing 5-receptors or 
K-receptors, we found low affinity ligand binding (Fig. 4.1.7., Table 4.1.2.). 
* C H O p c e l l s 
v C H 0 5 c e l l s 
• CHOK c e l l s 
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Figure 4.1.7. Homologous competition curves for [3H]DADN binding in membranes 
prepared from CHO cells expressing recombinant p-, 8- or K-opioid receptors. Data from 
cumulative experiments were normalized by the protein content and expressed as percent 
specific binding. Curves were analyzed by the one site competition model with the 
exception of S-receptors, where the sigmoid fitting with variable slope option was used. 
Points represent means ± SEM of 3-6 independent experiments each performed in 
duplicates. 
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Table 4.1.2. Summary of the [3H]DADN homologous competition experiments 
performed on membranes of Chinese Hamster Ovary (CHO) cells expressing different 
opioid receptor types 
Transfected receptor types on 
CHO cell membranes 
IC50 (nM) logIC5o±SE 
fl-opioid receptor 1.74 -8.76 ±0.037 
ô-opioid receptor 66.5 -7.18 ± 0.3197 
K-opioid receptor 1149 -5.94 ± 0.1126 
4.1.11. Stimulation of [35S]GTPyS binding by DADN in rat brain membranes 
The in vitro agonist property of DADN was determined by measuring the sodium 
index value: 40.2 ± 9.2 nM [159]. Following this a more functional approach, the 
[35S]GTPyS binding assay was used to study the agonist potency of the peptide. The 
stimulation of [35S]GTPyS binding to rat brain membranes was measured and compared 
to the effect exerted by the prototype p-opioid receptor agonist D A M G O (Fig. 4.1.8.). 
Both opioids produced dose-dependent increases in [35S]GTPyS binding. The ligand 
concentrations found to be necessary for half-maximal stimulation (EC50) were 2.4 ± 0.24 
pM for DADN and 0.11 ± 0.013 pM for DAMGO, respectively. The maximal 
stimulation induced by D A M G O was about 209 ± 7 %, while DADN produced a 
maximal stimulation of 199 ± 12 % at the highest ligand concentration used. Naloxone 
(10 pM) abolished the stimulating effects of both opioid agonists almost completely. In 
our study, we also examined the ability of type selective opioid receptor antagonists to 
reverse the G-protein activating effects of DADN. Co-incubation of 10 pM of DADN 
with p-opioid receptor selective antagonists: CTAP (10 pM) [73], or cyprodime(10 pM) 
[131] reversed the stimulating actions of the ligand. However, the K-selective antagonist 
(10 pM norBNI) [121], and the 8-specific antagonist TIPP (10 pM) [101] were only 
slightly effective in blocking DADN induced GTP-binding (Fig. 4.1.9.). 
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Figure 4.1.8. Stimulation of [35S]GTPyS binding to rat brain membranes by various 
concentrations of unlabeled DADN and DAMGO. Stimulation is given as a percentage of 
the non-stimulated (basal) level. Incubations were carried out for 60 min at 30°C. Points 
represent means ± SEM from 9 independent experiments, in triplicates. 
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Figure 4.1.9. Inhibition of agonist stimulated [35S]GTPyS binding by various selective 
antagonists in rat brain membranes. DADN was incubated in the absence or in the 
presence of opioid antagonists. The final concentration of the ligands was 10"5 M. 
Stimulation is given as a percentage of the non-stimulated (basal) level. Incubations were 
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carried out for 60 min at 30°C. Points represent means ± SEM from six independent 
experiments, each performed in triplicates. 
4.2. Functional characterization of 14-methoxymetopon 
4.2.1. Stimulation of [35S]GTPyS binding by 14-methoxymetopon 
A functional approach was used to establish the agonist potency of the unlabeled 
c 
epoxymorphinan compound. The stimulation of [ S]GTPyS binding to rat brain 
membranes was measured and compared to the effect exerted by the reference p-opioid 
receptor agonist DAMGO (Fig. 4.2.1.). Both opioids produced dose-dependent increases 
in [35S]GTPyS binding. The ligand concentrations calculated to be necessary for the half-
maximal stimulation (EC50) were 70.9 nM for 14-methoxymetopon and 499 nM for 
DAMGO (Table 4.2.1.). The maximal stimulation induced by DAMGO was 
approximately 218 % above the basal (non-stimulated) value, while 14-methoxymetopon 
reached a plateau at 257 %. 
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Fig. 4.2.1. Stimulation of [35S]GTPyS binding to rat brain membranes by various 
concentrations of 14-methoxymetopon ( • ) and DAMGO (A). Incubations were carried 
out for 60 min at 30°C. Points represent means ± SEM of 6-7 independent experiments, 
each performed in triplicate. 
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Table 4.2.1. Stimulation 
membranes 
of [35S]GTPyS binding by opioid agonists in rat brain 
Ligand EC50 (nM) Maximal stimulation (%) 
14-Methoxymetopon 70.9 ±8.5 257 ± 9 
DAMGO 499 ± 66 218 ± 10 
Morphine* 112 224 
* 
Endomorphin-1 44 279 
Endomorphin-2 57 265 
Rat brain membranes were incubated for 60 min at 30°C in the presence of increasing 
concentrations of agonists. Values represent the mean ± SEM of 6-7 independent 
experiments performed in triplicate. *Data from Spetea et al. [140] 
4.2.2. The ability of type selective opioid receptor antagonists to reverse the G-
protein activating effects of 14-methoxymetopon 
Naloxone (10 pM) completely abolished the stimulating effects of both opioid 
agonists (Fig. 4.2.2.). In our study, we also examined the ability of type selective opioid 
receptor antagonists to reverse the G-protein activating effects of 14-methoxymetopon 
(Fig. 4.2.2.). Incubation of 10 pM of either 14-methoxymetopon or D A M G O with p-
opioid receptor selective antagonists: CTAP (1 pM) [73] or cyprodime (10 pM) [131, 89] 
reversed the stimulating actions of the two agonists. However, the selective K- (nor-BNI, 
10 pM) and 5-(HS378, 10 pM) [142] opioid receptor ligands were only slightly effective 
in antagonizing 14-methoxymetopon or DAMGO induced GTP-binding (Fig. 4.2.2.). 
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Fig. 4.2.2. Inhibition of agonists stimulated [35S]GTPyS binding by naloxone (10 pM), 
CTAP (10 pM), cyprodime (10 pM), NorBNI (1 pM) and HS378 (1 pM) in rat brain 
membranes. 14-Methoxymetopon (10 pM) (white bars) or DAMGO (10 pM) (black bars) 
were incubated in the absence or in the presence of opioid antagonists. Incubations were 
carried out for 60 min at 30°C. Points represent means ± SEM of 6-7 independent 
experiments, each performed in triplicate. 
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5. DISCUSSION 
Integrity of the tyrosine moiety at the amino terminal of opioid peptides is an 
essential requirement for opioid activity. D-Amino acid substitutions at the second 
position can lead to enhanced activity of various opioid peptides, and increase the 
duration of their pharmacological effects as seen in a set of powerful synthetic peptides 
with different selectivities [126, 176, 151], Structural modifications targeted also the 
thioether (-SH) group of the Met5 side chain, which was shown to be readily oxidized 
resulting in methioninesulfoxide and/or methionine sulfone (Farkas, unpublished 
observation). Replacement of Met5 by Nle5 in Met-enkephalin-Arg-Phe (MERF) yielded 
peptides with different affinities depending on the conformation of the Nle (D-Nle or L-
Nle) inserted into the peptide backbone. The analogues containing L-Nle5 substitutions 
showed binding affinities similar to the parent compound in [3H]MERF and [3H]naloxone 
binding studies [17]. The stability of L-Nle5 containing peptides was better compared to 
the original ligand due to the lack of the methionine side chain. In this peptide one does 
not have to reckon with the fact that the thioether group of methionine oxidates relatively 
quickly. In opioid peptides with Tyr-Gly N-terminal dipeptide, substitution of Gly2 with 
D-Ala2 protects the peptide against aminopeptidases [9], so this replacement increases the 
ligand's in vivo and in vitro stability without decreasing the opioid activity. The D-Ala2, 
D-Nle5 containing analogue (DADN), contrary to the other derivatives, had only 
moderate affinities in competing with [3H]MERF or [3H]naloxone [17], whereas it 
displayed the highest potency in producing antinociception following intrathecal 
administration [153]. The contradiction between the in vivo results and the results yielded 
from the in vitro binding experiments with [3H]MERF and [3H]naloxone, can be resolved 
if we presume a fundamental change in receptor selectivity of the peptide. In our studies 
DADN showed higher affinity for p-opiate-binding sites as measured with [3H]DAMGO. 
The reason for this is likely due to the presence of D-Nle5 side chain in the heptapeptide 
backbone. It is well known that the incorporation of D-amino acids into helical structured 
oligopeptides causes a change in the 3D structure by destabilizing the a-helix [24]. In 
heptapeptides the chance of the peptide folding into a-helical conformation is limited (but 
with a well-defined set of interactions a-helix may form in these short peptides) [33], It is 
assumed, that the active conformation of DADN, which forms near the extracellular 
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surface of the receptor molecule, favours interactions with p-opiate receptors above all. 
While the conformation of L-Nle5 or L-Met5 containing peptides might be different. The 
high potency of DADN in in vivo tests can be ascribable by conformational and stability 
factors and also by differences in solubility, because we found this peptide to be the most 
lipid soluble among all MERF analogues synthesized. Deletion of the N-terminal domain 
(amino acids 1-66) or the C-terminal 33 amino acids of the p-receptor produces little 
change in receptor binding affinities and selectivities, suggesting that the region critical 
for binding lies within the transmembrane domains and the extracellular loops [ 1 5 2 ] , 
Several amino acids within the transmembrane domains of the p-receptor have been 
shown to be critical for opioid-receptor binding [152]. His297 in TM6 is critical for 
opioid-receptor binding. Asn150 in TM3 and Tyr326 in TM7 further define the binding 
pocket [88]. Therefore the pronounced hydrophobicity of the ligand can increase a tight 
interaction with the p-binding site. The increased lipophilicity of DADN favours the 
transport of the ligand through the blood-brain barrier and might take part in the reported 
analgesic effect of the molecule [153]. Specific binding of [3H]DADN to native opioid 
receptors was demonstrated to be of high affinity, reversible, saturable, and 
stereoselective. Despite the original preference of MERF for K2- and 8-opioid receptors, 
DADN seems to possess altered selectivity toward p-opioid-binding sites. Changes in the 
receptor-type preference of the peptide, increased chemical and enzymatic stability, and 
higher hydrophobicity (lipid solubility) all account for the effectiveness of the compound 
obtained in biochemical and pharmacological assays [153]. The binding properties of the 
new radiolabeled heptapeptide enkephalin, [3H]DADN, were determined in rat brain 
membranes. The kinetic experiments showed that the formation of ligand-receptor 
complexes (association) occurred rapidly according to pseudo-first order kinetics. 
Ligand-induced dissociation of the radioprobe proceeded also in monophasic manner, 
proving the reversibility of the binding interaction. Equilibrium saturation experiments 
and Scatchard plots revealed that a single class of opioid-binding sites was labeled by this 
radioligand. The affinity for this site is in good agreement with the kinetically determined 
values for [3H]DADN specific binding. The capacity was found to be 72 ± 13 fmol/mg 
protein. Similar values were described in rat brain membranes using various p-opioid 
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receptor selective radioligands, such as [3H]cyprodime [89], [3H]dermorphin [2], and 
[3H]TAPP [141]. 
Heterologous competition assays with different opioid compounds revealed that 
[3H]DADN specific binding is effectively inhibited by p-selective ligands, whereas K-
and 8-specific ligands displayed lower affinity (the rank order of potency is: p > 8> K). 
This selectivity pattern verifies our previous observations with unlabeled DADN and 
confirms that modifications in the amino acid sequence of MERF can fundamentally alter 
the selectivity of the peptide (MERF: K2/8 -—DADN: p). 
Interaction of DADN with opioid receptors has been characterized in the presence 
of nearly physiological Na+ ion concentrations (100 mM). It is well established that 
agonists have lower affinity for opioid receptors in the presence of Na+ ions, whereas 
antagonist binding is less affected [114]. It has been hypothesized that Na+ ions 
allosterically induce a conformational change in the protein structure which renders the 
receptor site less likely to bind agonists and more likely to bind antagonists. In vitro 
agonist nature of the peptide has been confirmed by calculating sodium index value for 
unlabeled DADN in [3H]naloxone binding assays. The direct inhibitory effect of Na+ ions 
on [3H]DADN specific binding (figure not shown) is also in agreement with the agonist 
character of the peptide. 
DADN was also studied by the means of in vivo pharmacological and in vitro 
functional biochemical tools. It is well known that the spinal cord has a significant role in 
the opioid-induced antinociception [53, 60, 54], Our in vivo results suggest that DADN 
has high antinociceptive potency at spinal level mainly by the activation of p-opioid 
receptors. Specific ligand binding sites related to the spinal opioid receptors mediating 
the antinociceptive in vivo effect of DADN could be observed in crude membrane 
fractions of rat spinal cord tissues by direct radioreceptor binding assays. For these 
studies, a radiolabeled derivative of DADN with high specific activity ([3H]DADN, 41 
Ci/ mmol) was applied [159]. The number and affinity of specific [3H]DADN binding 
sites were determined by equilibrium homologous competition experiments. High-
affinity binding interaction (Kj = 0.4 nM) was obtained in spinal cord membrane 
preparation. The density of spinal recognition sites labeled by [3H]DADN was found to 
be 72 fmol/mg of membrane protein, a value close to those observed in rat brain 
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membranes [159]. Basically similar capacities ( B ^ values) for the p-opioid binding sites 
have been described in brain [140, 89, 141, 2] and spinal cord tissues [125, 177] using 
various p-receptor selective radioligands. 
Recent cDNA cloning studies have revealed primary structures of g-, 5-, K-opioid 
receptors [66, 71]. The availability of the cloned opioid receptors allowed studies of 
individual receptor types with regard to pharmacological profile, structure-function 
analysis, cellular effector coupling, and regulation of expression. Transfection of an 
individual opioid receptor in various heterologous host cells can now be used to provide a 
pure, homogenous population of receptors. Several cell lines expressing cloned mouse, 
rat, or human p-opioid receptors are good models for determining binding affinities and 
selectivities of new opioid drug candidates. The cloned p-opioid receptors have been 
expressed in epithelial cells like monkey fibroblast (COS cells) [166] and Chinese 
hamster ovary (CHO cells) [7]. Yeast cells [154] and excitable cells, such as the GH3 
pituitary cell line [117] have also been used to investigate pharmacological properties of 
cloned p-opioid receptors. The only disadvantage of using transfected cell cultures for 
studying receptor function is that these artificial expression systems may provide an 
altered membrane environment, e.g., really different sets of regulatory G-proteins, 
comparing with membranes from natural tissue sources. 
In our experiments with DADN, Chinese hamster ovary cells stably expressing 
individual opioid receptors (CHOp, CH05 and C H O K ) were used. The synthetic 
heptapeptide ligand was shown to bind specifically to each of the receptor types, although 
with different affinity. The rank order of the potency of DADN in displacing [3H]DADN 
was p > 5 > K at the cloned receptor-system. Nearly the same selectivity profile for 
DADN was obtained in heterologous competition studies performed on rat brain 
membranes canying native opioid receptors [159]. 
Opioid receptors are seven transmembrane (7TM) domain containing receptors 
and are known to exert their biological functions by interacting with the heterotrimeric G-
proteins. Agonist binding to the receptors in the GPCR family results in conformational 
change in the binding domain permitting subsequent activation of G-proteins. Activation 
and regulation of these proteins are key elements in the transmembrane signalling 
triggered by opioid ligands and are believed to be involved in the cellular mechanisms of 
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drug addiction [144]. One approach to examine the signal transduction in the membrane 
preparations is by measuring the binding of the nonhydrolizable GTP analogue, 
[35S]GTPyS, as a function of ligand concentration [158], In our study, DADN activated 
G-proteins as indicated by the stimulation of the [35S]GTPyS binding to rat brain 
membranes in a concentration dependent manner, exhibiting an EC50 of 2.3 pM which is 
approximately 23-fold higher than for DAMGO. Both peptides displayed quite similar 
affinities in receptor binding assays [159], so the higher EC50 values for DADN in the 
functional test should reflect a decreased potency of the peptide comparing with the 
effect exerted by DAMGO. The reason for the lowered potency remains unclear, 
although the basis for efficacy is more complex and must involve activation-associated 
conformational changes [79]. In our GTPyS assays, DADN is as efficient as DAMGO: 
the maximal stimulatory effect was approximately 200% for both peptides. These 
functional data are also consistent with our previous findings on the agonist character of 
DADN by demonstrating a rightward shift of the [3H]naloxone competition curves in the 
presence of nearly physiological concentration of sodium ions [159]. Stimulation of 
DADN could be prevented by 10 pM naloxone, indicating an opioid receptor-mediated 
action. Moreover, the reversibility of these effects was shown with antagonists acting 
selectively at the p-opioid receptor. The somatostatin analogue peptide C T A P [73] and 
the nonpeptide opioid antagonist cyprodime [131] potentially and effectively inhibited 
the activation of GTP-binding proteins as measured by [35S]GTPyS. In contrast, the 
stimulatory action of DADN was only slightly reversed by the K-selective norBNI [121] 
and 8-selective TIPP [101] opioid receptor antagonists. Based on these findings, DADN 
is a potent opioid agonist and its action was demonstrated to be mediated via the p-opioid 
receptor. Altogether, incorporation of D-alanine2 and D-norleucine5 into the naturally 
occurring proenkephalin-derived heptapeptide MERF resulted in improved analgesic 
potency and changed opioid receptor selectivity of the compound. [3H]DADN recognized 
and labeled p-opioid receptors in rat brain membrane preparations. Importantly, the 
binding of this radioligand fulfilled the criteria of reversibility, saturability, 
stereoselectivity, and low non-specific binding necessary for valuable radioligands. These 
properties of [3H]DADN combined with its satisfactory purity, stability, and high specific 
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radioactivity (41 Ci/mmol), make this radioligand a very promising tool for analyzing the 
properties and function of the p-opioid receptor. 
The highly potent epoxymorphinan analogue, 14-methoxymetopon activated G-
proteins by stimulating [35S]GTPyS binding to rat brain membranes in a concentration-
dependent manner, exhibiting an EC50 of 70.9 nM, which is approximately sevenfold and 
twofold lower than for D A M G O and morphine, respectively. (Note that the lower EC5 0 
value equals higher potency). These functional data confirm previous findings in guinea-
pig ileum bioassay on the agonist character of 14-methoxymetopon [39], The EC 5 0 value 
of 14-methoxymetopon was determined to be similar to those reported for the 
endogenous p-opioid peptides endomorphin-1 and endomorphin-2 [140], The maximal 
effect was approximately 257% of the nonstimulated level for 14-methoxymetopon, 
while it was lower by approximately 15% for p-opioid agonists D A M G O and morphine. 
Stimulation of both 14-methoxymetopon and D A M G O could be prevented by 10 pM 
naloxone, indicating an opioid receptor-mediated action. Moreover, the reversibility of 
these effects was shown with antagonists acting selectively at the p-opioid receptor. The 
somatostatin analogue peptide CTAP [73] and the nonpeptide opioid antagonist 
cyprodime [131, 90] could potentially and effectively inhibit the methoxymetopon 
mediated activation of GTP-binding protein as measured by the binding of GTPyS. In 
contrast, the stimulatory action of 14-methoxymetopon and D A M G O was not reversed by 
the selective K- (nor-BNI) [121, 89] and 8- (HS378) [142] opioid receptor antagonists. 
Based on these findings, 14-methoxymetopon is a potent opioid agonist and its action 
was demonstrated to be mediated via the p-opioid receptor. 
14-methoxymetopon has a high analgesic potency with extremely mild side 
effects compared to morphine, e.g. minimum physical dependence, tolerance, respiratory 
depression and constipation. It is one of the few nonpeptide p-opioid receptor agonists 
available in radiolabeled form up to now. All the properties mentioned above should 
make this ligand an important and useful tool in probing p-opioid receptor mechanisms, 
as well as to promote a further understanding of the opioid system at the cellular and 
molecular level. 
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6. S U M M A R Y 
p-Opioids remain the prototypic opiate analgesics. Despite their widespread 
utility, the many side effects have led to attempts to generate molecules exhibiting a 
favourable dissociation between analgesic activity and the side effects. The present study 
focused on the biochemical and functional analysis of opioid ligands acting at the p-
opioid receptor. The studied ligands include 14-methoxymetopon and D-Ala2-D-Nle5-
MERF. The main findings are the following: 
1. Incorporation of D-Ala2 and D-Nle5 into MERE resulted in better stability and 
improved analgesic potency of the compound. 
2. Specific binding of [3H]DADN to rat brain membranes was of high affinity, reversible, 
saturable, and stereoselective. DADN exhibits preference toward p-opioid-binding sites. 
3. Kinetic experiments showed that the association occurred rapidly according to pseudo-
first order kinetics. Ligand-induced dissociation of the radioprobe proceeded in a 
monophasic manner. Equilibrium saturation experiments revealed that a single class of 
opioid-binding sites was labeled by this radioligand. 
4. Heterologous competition assays with different opioid compounds revealed that the 
rank order of potency is: p > 5> K for [3H]DADN specific binding. 
5. High-affinity binding interaction was obtained in spinal cord membrane preparation. 
6. The rank order of the potency of DADN in displacing [3H]DADN was p > 5> K in the 
cloned receptor-system (CHO cells). 
7. Both D A D N and 14-methoxymetopon activated G-proteins in a concentration 
dependent manner. G-protein stimulation of DADN and 14-methoxymetopon could be 
prevented by naloxone. C T A P and cyprodime (p-receptor selective antagonists) 
effectively inhibited the activation of G-proteins in the case of both ligands. The 
stimulatory action of DADN was only slightly reversed by the K-selective antagonist 
norBNI and 5-selective antagonist TIPP and was not reversed by the K-selective 
antagonist nor-BNI and 5-selective antagonist HS378 in the case of 14-methoxymetopon. 
DADN and 14-methoxymetopon are potent opioid agonists and their actions are mediated 
via the p-receptor. The p-opioid system is extremely complicated and getting 
increasingly complex every year. There is little question more surprises will be coming. 
In the words of Yogi Berra, " It ain't over 'til it's over". 
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